Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Enterprise Value (2019 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Enterprise Value for 9 consecutive years, with -$559.5 million as the latest value for Q1 2026.

  • For Q1 2026, Enterprise Value rose 29.44% year-over-year to -$559.5 million; the TTM value through Mar 2026 reached -$559.5 million, up 29.44%, while the annual FY2025 figure was -$628.1 million, 5.53% up from the prior year.
  • Enterprise Value hit -$559.5 million in Q1 2026 for Bicycle Therapeutics, up from -$628.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$100.0 million in Q1 2022 and bottomed at -$961.4 million in Q2 2024.
  • Average Enterprise Value over 5 years is -$543.0 million, with a median of -$559.5 million recorded in 2026.
  • Year-over-year, Enterprise Value soared 48.95% in 2022 and then tumbled 193.81% in 2023.
  • Bicycle Therapeutics' Enterprise Value stood at -$339.2 million in 2022, then crashed by 55.22% to -$526.4 million in 2023, then fell by 26.31% to -$664.9 million in 2024, then increased by 5.53% to -$628.1 million in 2025, then rose by 10.92% to -$559.5 million in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$559.5 million, -$628.1 million, and -$648.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.